Your session is about to expire
← Back to Search
Olaparib + Durvalumab for Small Cell Lung Cancer
Study Summary
This trial is testing a combination of drugs to see if it can help people with a specific type of lung cancer that has transformed into another cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 80 Patients • NCT03015129Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently participating in another clinical trial or receiving treatment.I have an autoimmune disease that needs steroids or a primary immunodeficiency.You have had allergic reactions to drugs similar to olaparib or durvalumab.I am not pregnant or breastfeeding.I have had or refused platinum-based chemotherapy for my cancer.I haven't had major surgery in the last 28 days, except for minor procedures to relieve symptoms.I am not taking strong or moderate drugs that affect liver enzyme CYP3A4, except for certain heart medications.I can take care of myself but might not be able to do heavy physical work.I have had an organ or bone marrow transplant.I haven't taken strong immune-weakening medicines in the last 14 days, except for small doses of steroids or short-term use.I have been diagnosed with myelodysplastic syndrome or acute myeloid leukemia.I do not have any severe illnesses that could worsen with the study treatment.I can't take pills by mouth or have stomach issues affecting medicine absorption.My liver is functioning well according to recent tests.I am using or willing to use effective birth control during and after the study.I don't have active brain metastases or have been stable for 2 weeks without steroids.My lung cancer changed to a different type after treatment with a specific medication.My kidney function is within the required range for the study.Your heart's electrical activity shows signs of uncontrolled or reversible heart problems, or you have a congenital long QT syndrome.I do not have an active infection like TB, hepatitis B, or hepatitis C.I am HIV-positive but have been stable on antiretroviral therapy for over 5 years with an undetectable viral load and CD4 count over 150.I have lasting side effects from cancer treatment, but not hair loss.I have received high-dose chest radiation within the last 2 weeks.I have not had cancer treatment or major surgery in the last 2 weeks.I have received palliative radiation within the last 24 hours.I am 18 years old or older.Your blood counts should be at a certain level within the last 28 days before joining the study. This includes white blood cells, neutrophils, platelets, and hemoglobin.You must have a disease that can be measured according to specific guidelines.
- Group 1: 1/Arm 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can people still join this scientific experiment?
"According to the details listed on clinicaltrials.gov, this health trial has been recruiting since its initial posting on July 7th 2021 and is up-to-date as of October 4th 2022."
Can you give me a synopsis of the research conducted involving Durvalumab?
"Presently, there are 484 studies related to Durvalumab with 75 of them in the final stage. Primarily situated in Houston, Texas, these trials have 19978 sites around the world."
To what conditions is Durvalumab commonly prescribed?
"Durvalumab is an effective pharmacotherapy for this condition and other illnesses such as primary peritoneal cancer, advance directives, and additional diseases."
How many participants are being recruited for this trial?
"Affirmative, the information on clinicaltrials.gov shows that this experiment is actively recruiting participants. Initially posted on July 7th 2021 and recently updated October 4th 2022, it seeks a total of 14 individuals at one location."
Has Durvalumab been accredited by the FDA?
"Durvalumab's safety rating is 2 as this Phase 2 trial has evidence of its security, yet not enough to prove effectiveness."
Has this type of research been conducted previously?
"Durvalumab has been studied since 2005, when its first trial was sponsored by AstraZeneca. This initial study involving 98 patients would eventually lead to the drug's Phase 1 approval. Presently, 484 active trials are running in 65 countries and 1846 cities for Durvalumab."
Share this study with friends
Copy Link
Messenger